로딩 중...
52주 최고가 대비 98.4% 위치
Materialise NV provides additive manufacturing and medical software tools, and 3D printing services in the Americas, Europe, Africa, and the Asia-Pacific. The company operates through three segments: Materialise Software, Materialise Medical, and Materialise Manufacturing. The Materialise Software segment offers proprietary software through programs and platforms that enable and enhance the functionality of 3D printers, and printing operations. Its software interfaces between various types of 3D printers; and various software applications and capturing technologies, including computer-aided design/computer-aided manufacturing packages and 3D scanners; a MES, software providers. This segment serves 3D printing machine manufacturers; production companies and contract manufacturers in automotive, aerospace, consumer goods, and hearing aid industries; and 3D printing service bureaus through its sales force, website, and third-party distributors. The Materialise Medical segment provides medical software that allows medical-image based analysis, planning, and engineering, as well as patient-specific design and printing of surgical devices and implants. It serves medical device companies, hospitals, universities, research institutes, and industrial companies. The Materialise Manufacturing segment provides 3D printing services, design and engineering services, and rapid prototyping and additive manufacturing of production parts to customers serving the automotive, consumer goods industrial goods, semiconductor, art and architecture and aerospace markets. The company has collaboration agreements with Zimmer Biomet Holdings, Inc.; Encore Medical, L.P.; DePuy Synthes Companies of Johnson & Johnson; Limacorporate Spa; Mathys AG; Smith & Nephew Inc.; Corin Ltd; Medtronic Inc.; and Abbott Laboratories Inc. Materialise NV was incorporated in 1990 and is headquartered in Leuven, Belgium.
SEC 13F 공시 기준 · 2026-Q1
SEC 13F 공시 기준 데이터입니다. 실제 현재 보유 현황과 다를 수 있으며, 투자 자문·권유·추천이 아닙니다.
| 재무 항목 | 2021년 | 2022년 | 2023년 | 2024년 | 2025년 |
|---|---|---|---|---|---|
| 주요 재무실적 (USD) | |||||
| 매출액 | - | $232.0M | $256.1M | $266.8M | $267.6M |
| 영업이익 | - | $-3.6M | $15.0M | $9.4M | $8.9M |
| 당기순이익 | - | $-2.1M | $6.7M | $13.4M | $7.7M |
| 잉여현금흐름 (FCF) | - | $-2.5M | $8.4M | $5.1M | $9.1M |
| 수익성 비율 | |||||
| 영업이익률 | - | -1.5% | 5.9% | 3.5% | 3.3% |
| 순이익률 | - | -0.9% | 2.6% | 5.0% | 2.9% |
| ROE (자기자본이익률) | - | -0.9% | 2.8% | 5.4% | 3.0% |
| ROA (자산이익률) | - | -0.5% | 1.7% | 3.4% | 1.8% |
| 성장성 비율 | |||||
| 매출 성장률 (YoY) | - | - | 10.4% | 4.2% | 0.3% |
| EPS 성장률 (YoY) | - | - | 375.0% | 109.1% | -43.5% |
| 투자 지표 & 가치배수 | |||||
| PER (주가수익배수) | - | - | 51.5x | 36.4x | 42.4x |
| PBR (주가순자산배수) | - | 2.7x | 1.4x | 2.0x | 1.3x |
| PSR (주가매출배수) | - | 2.6x | 1.3x | 1.8x | 1.2x |
| FCF Yield | - | -0.4% | 2.5% | 1.0% | 2.8% |
| 재무 건전성 (안정성) | |||||
| 부채비율 (D/E) | - | 0.35 | 0.27 | 0.17 | 0.25 |
| 유동비율 | - | 2.04 | 1.97 | 1.86 | 2.43 |
TAIWAN SEMICONDUCTOR-SP ADR
$446.69
$2.32T